Suppr超能文献

通过分子靶向药物抑制细胞应激防御机制治疗肝细胞癌的新策略

New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms.

作者信息

Honma Yuichi, Harada Masaru

机构信息

Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.

出版信息

J UOEH. 2014 Dec 1;36(4):229-35. doi: 10.7888/juoeh.36.229.

Abstract

The prognosis of advanced hepatocellular carcinoma (HCC) has remained very poor.It has recently been reported that the molecular targeting agent sorafenib can improve the prognosis of patients with advanced HCC. However, the detailed mechanisms of sorafenib, especially its direct effects on hepatoma and hepatocyte cells, are poorly understood, making a more detailed investigation about the molecular mechanism of sorafenib necessary. Endoplasmic reticulum (ER) stress is related to the pathophysiology of various liver diseases, including chronic viral hepatitis, alcoholic and nonalcoholic steatohepatitis and HCC. In this regard, our recent data examining the molecular effects of sorafenib focused on the cellular defense mechanisms from ER stress, the unfolded protein response (UPR) and keratin phosphorylation, demonstrated that sorafenib inhibited both important cytoprotective mechanisms, UPR and keratin phosphorylation, and enhances the anti-tumor effect in combination with proteasome inhibitors. This review summarizes the cytoprotective mechanisms from ER stress and our results about the direct effect of sorafenib on the cytoprotective mechanisms.

摘要

晚期肝细胞癌(HCC)的预后一直很差。最近有报道称,分子靶向药物索拉非尼可改善晚期HCC患者的预后。然而,索拉非尼的详细作用机制,尤其是其对肝癌细胞和肝细胞的直接作用,目前尚不清楚,因此有必要对索拉非尼的分子机制进行更详细的研究。内质网(ER)应激与包括慢性病毒性肝炎、酒精性和非酒精性脂肪性肝炎以及HCC在内的各种肝脏疾病的病理生理学有关。在这方面,我们最近关于索拉非尼分子效应的数据集中在内质网应激的细胞防御机制、未折叠蛋白反应(UPR)和角蛋白磷酸化上,结果表明索拉非尼抑制了重要的细胞保护机制UPR和角蛋白磷酸化,并与蛋白酶体抑制剂联合增强了抗肿瘤作用。本综述总结了内质网应激的细胞保护机制以及我们关于索拉非尼对细胞保护机制直接作用的研究结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验